This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Research Model Assesses Indirect Economic Implications Of Musculoskeletal Disorders And Treatment

AAOS study measures the societal and economic value of MSK care

ROSEMONT, Ill., March 15, 2013 /PRNewswire-USNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) today introduced a methodological model to evaluate musculoskeletal (MSK)-related limitations and infer indirect economic outcomes and the societal value of specific orthopaedic surgery procedures. The AAOS study, "Modeling the Indirect Economic Implications of Musculoskeletal Disorders and Treatment ," published in BioMed Central's open access journal, Cost Effectiveness and Resource Allocation , is a comprehensive assessment to-date of the economic impact of MSK disorders.

Importantly, this model provides a foundation to assess the value of procedures and health services, both within and beyond the field of orthopaedics, where primary data are limited.

"From the perspectives of the patient, employers, and society, the 'value' of appropriate medical treatment extends beyond current and future medical expenditures and includes things like whether people can maintain their own independence, remain productively employed, avoid payments for disability or long-term care, and have an overall improvement of their quality of life," said John R. Tongue, MD, AAOS president. "With this new methodology, we are able to examine, for the first time, MSK care as it relates to specific conditions, and uncover the societal and economic benefits currently overlooked in the larger health care value discussion. In an increasingly cost- and quality-conscious health care environment, this analysis provides critical insight into what the true value of orthopaedic care means for patients."

MSK disorders and diseases are the leading cause of disability in the United States, affecting the physical, financial and emotional well-being of millions of Americans each year. While many studies have quantified the burden of MSK disorders and the cost-effectiveness of treatment, few studies have looked at the impact of indirect cost measures, such as employability and loss of income, and the value these services provide to workers and their families, employers and society.

The published research suggests that:

  • Physical impairments associated with MSK disorders reduce household income and the likelihood of employment, and increase missed work days and disability pay for those who are employed.
  • Appropriate treatment of MSK disorders has the potential to significantly reduce indirect costs and is associated with net economic benefits to society.

To conduct the study, AAOS evaluated data from more than 185,000 people included in the National Health Information Survey (NHIS) and measured the relationship between physical limitations associated with MSK disorders and indirect indicators of cost, including employability, missed days of work, household income, and disability income. Using the NHIS findings and data from clinical studies, AAOS created an index that estimated the impact of specific orthopaedic surgery procedures on physical limitations and indirect costs.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs